ES2569193T3 - Antagonistas de TRPV4 - Google Patents
Antagonistas de TRPV4 Download PDFInfo
- Publication number
- ES2569193T3 ES2569193T3 ES12814591T ES12814591T ES2569193T3 ES 2569193 T3 ES2569193 T3 ES 2569193T3 ES 12814591 T ES12814591 T ES 12814591T ES 12814591 T ES12814591 T ES 12814591T ES 2569193 T3 ES2569193 T3 ES 2569193T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- het
- halo
- hydrogen
- 3alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003567 TRPV4 Human genes 0.000 title 1
- 101150098315 TRPV4 gene Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- 125000001475 halogen functional group Chemical group 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- -1 tetrahydrofurfuryl Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de Fórmula (I):**Fórmula** en la que: R1 es hidrógeno, alquilo C1-3, CH2OH, CH2-O-CH3, CH2OCH2Ph, CH2CN, CN, halo o C(O)OCH3; R2 es independientemente hidrógeno, CN, CF3, halo, SO2alquilo C1-3, alquilo C1-3 o C≡CH; R3 es hidrógeno, alquilo C1-2, CF3 u OH; R4 es hidrógeno, halo o alquilo C1-3; X es CR4 o N; A es (CH2)n -Het; o A es (CH2)n-(CRaRb)-(CH2)m-Het; Ra es hidrógeno o alquilo C1-3, en el que el alquilo C1-3 puede estar sustituido adicionalmente con uno o más halos; Rb es alquilo C1-3; o Ra y Rb, junto con el átomo de carbono al que están unidos, forma un grupo cicloalquilo C3-6; uno o más de los átomos de carbono en el grupo cicloalquilo C3-6 formado por Ra y Rb pueden estar reemplazados con oxígeno para formar un oxetano, tetrahidrofurilo o tetrahidropiranilo; uno de los átomos de carbono en el grupo cicloalquilo C3-6 formado por Ra y Rb, puede estar reemplazado con nitrógeno para formar un grupo pirrolidinilo o piperidinilo; Het es:**Fórmula** en la que Het puede estar sustituido con uno, dos o tres sustituyentes seleccionados entre: halo, alquilo C1-5, CN, CH2F, CHF2, CF3, cicloalquilo C3-6, (CH2)n-O-alquilo C1-3, (CH2)n-fenilo, (CH2)n-piridilo, pirimidinilo, pirazinilo, CH(CH3)-O-alquilo C1-3, CH(OH)-alquilo C1-5, C(CH3)2 - R5, C(O)N(CH3)p, N(alquilo C1-3)p, NH2, C(O)NH2, oxetano, oxetano-CH3, tetrahidrofurfurilo, tetrahidropiranilo, morfolinilo o pirazolilo; en la que el sustituyente fenilo, pirazolilo, y piridilo en el Het puede estar adicionalmente sustituido con uno o dos sustituyentes seleccionados entre: halo, CN, OCH3, alquilo C1-3 o CF3; y el sustituyentes alquilo C1-5 y cicloalquilo C3-6 en el Het puede estar adicionalmente sustituido con CN u OH; R5 es CN, O-alquilo C1-4, (CH2)m - OH, (CH2)p - O - C(O) - O -alquilo C1-5 o O-(CH2)p-O -R6; R6 es alquilo C1-4 o P(O)2(CH3)2; n es independientemente 0, 1 ó 2; m es independientemente 0, 1 ó 2; p es independientemente 1 ó 2; e y es 1, 2 ó 3; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498110P | 2011-06-17 | 2011-06-17 | |
US201161498110P | 2011-06-17 | ||
PCT/US2012/042622 WO2013012500A1 (en) | 2011-06-17 | 2012-06-15 | Trpv4 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2569193T3 true ES2569193T3 (es) | 2016-05-09 |
Family
ID=47558389
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES16162808T Active ES2688733T3 (es) | 2011-06-17 | 2012-06-15 | Combinaciones de antagonistas de trpv4 |
ES12814591T Active ES2569193T3 (es) | 2011-06-17 | 2012-06-15 | Antagonistas de TRPV4 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES16162808T Active ES2688733T3 (es) | 2011-06-17 | 2012-06-15 | Combinaciones de antagonistas de trpv4 |
Country Status (38)
Country | Link |
---|---|
US (1) | US9187464B2 (es) |
EP (2) | EP3121177B1 (es) |
JP (1) | JP5969017B2 (es) |
KR (1) | KR101870003B1 (es) |
CN (1) | CN103732583B (es) |
AR (1) | AR086958A1 (es) |
AU (1) | AU2012284540B2 (es) |
BR (1) | BR112013032391B1 (es) |
CA (1) | CA2839743C (es) |
CL (1) | CL2013003602A1 (es) |
CO (1) | CO6821953A2 (es) |
CR (1) | CR20130671A (es) |
CY (1) | CY1117792T1 (es) |
DK (1) | DK2721016T3 (es) |
DO (1) | DOP2013000307A (es) |
EA (1) | EA023616B1 (es) |
ES (2) | ES2688733T3 (es) |
HK (1) | HK1195068A1 (es) |
HR (1) | HRP20160539T1 (es) |
HU (1) | HUE029594T2 (es) |
IL (1) | IL229872A (es) |
JO (1) | JO3154B1 (es) |
MA (1) | MA35184B1 (es) |
ME (1) | ME02416B (es) |
MX (1) | MX337440B (es) |
MY (1) | MY173521A (es) |
PE (1) | PE20141943A1 (es) |
PL (1) | PL2721016T3 (es) |
PT (1) | PT2721016E (es) |
RS (1) | RS54858B1 (es) |
SG (1) | SG195106A1 (es) |
SI (1) | SI2721016T1 (es) |
SM (1) | SMT201600150B (es) |
TW (1) | TWI538912B (es) |
UA (1) | UA113963C2 (es) |
UY (1) | UY34138A (es) |
WO (1) | WO2013012500A1 (es) |
ZA (1) | ZA201308816B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5969016B2 (ja) | 2011-06-17 | 2016-08-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Trpv4拮抗薬 |
EP2720697B1 (en) | 2011-06-17 | 2016-07-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Trpv4 antagonists |
WO2013146754A1 (ja) | 2012-03-27 | 2013-10-03 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素5員環誘導体 |
JPWO2015046193A1 (ja) | 2013-09-25 | 2017-03-09 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素環式アミン誘導体 |
US10968209B2 (en) | 2016-05-19 | 2021-04-06 | Glaxosmithkline Intellectual Property (No.2) Limited | TRPV4 antagonist |
EP3458451B1 (en) * | 2016-05-19 | 2020-06-03 | Glaxosmithkline Intellectual Property (No. 2) Limited | Trpv4 antagonist |
PE20190706A1 (es) | 2016-10-03 | 2019-05-17 | Janssen Pharmaceutica Nv | Analogos novedosos de carbanucleosidos sustituidos de sistema anular monociclico y bicicilo para su uso como inhibidores de prmt5 |
WO2018185701A1 (en) | 2017-04-06 | 2018-10-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Trpv4 antagonists as antitussive agents |
BR112020008157A2 (pt) * | 2017-11-01 | 2020-10-06 | Bristol-Myers Squibb Company | compostos espirocíclicos como moduladores do receptor farnesoide x |
WO2021170811A1 (en) | 2020-02-27 | 2021-09-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treating eye disease using trpv4 antagonists |
CA3180132A1 (en) | 2020-04-30 | 2021-10-30 | Raqualia Pharma Inc. | Pyrimidin-4(3h)-one derivatives as trpv4 antagonists |
CN111704613B (zh) * | 2020-06-23 | 2021-07-06 | 中国人民解放军军事科学院军事医学研究院 | 咪唑类衍生物及其作为trpv4抑制剂的用途 |
CA3189206A1 (en) * | 2020-07-16 | 2022-01-20 | Raqualia Pharma Inc. | Trpv4 inhibitor as therapeutic agent for ocular disease |
WO2024011214A1 (en) | 2022-07-08 | 2024-01-11 | Actio Biosciences, Inc. | Therapeutic compounds and methods |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4549534B2 (ja) * | 1998-05-26 | 2010-09-22 | 中外製薬株式会社 | 複素環を有するインドール誘導体及びモノ又はジアザインドール誘導体 |
WO2005007648A2 (en) * | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
CA2630617C (en) * | 2005-11-23 | 2014-03-25 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
WO2007067756A2 (en) | 2005-12-08 | 2007-06-14 | Amphora Discovery Corporation | Certain chemical entities, compositions, and methods for modulating trpv1 |
WO2007073505A2 (en) * | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | Trpa1 inhibitors for treating pain |
TW200819457A (en) * | 2006-08-30 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
US20100286151A1 (en) * | 2007-02-01 | 2010-11-11 | Jonathan Bentley | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders |
GB0707934D0 (en) * | 2007-04-24 | 2007-05-30 | Glaxo Group Ltd | Chemical compounds |
WO2009023539A2 (en) * | 2007-08-09 | 2009-02-19 | Abbott Laboratories | Tetrahydropyridine carboxamide derivatives as trpvl antagonists |
TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
WO2010011914A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
JP2012006837A (ja) * | 2008-09-30 | 2012-01-12 | Mochida Pharmaceut Co Ltd | 2−インドールアクリルアミド類縁体 |
WO2012024183A1 (en) | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
JP5969016B2 (ja) * | 2011-06-17 | 2016-08-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Trpv4拮抗薬 |
EP2720697B1 (en) * | 2011-06-17 | 2016-07-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Trpv4 antagonists |
-
2012
- 2012-06-14 JO JOP/2012/0159A patent/JO3154B1/ar active
- 2012-06-15 SI SI201230564A patent/SI2721016T1/sl unknown
- 2012-06-15 BR BR112013032391-4A patent/BR112013032391B1/pt active IP Right Grant
- 2012-06-15 PE PE2013002807A patent/PE20141943A1/es active IP Right Grant
- 2012-06-15 US US14/125,378 patent/US9187464B2/en active Active
- 2012-06-15 RS RS20160417A patent/RS54858B1/sr unknown
- 2012-06-15 UA UAA201400152A patent/UA113963C2/uk unknown
- 2012-06-15 AR ARP120102143A patent/AR086958A1/es active IP Right Grant
- 2012-06-15 PL PL12814591T patent/PL2721016T3/pl unknown
- 2012-06-15 MX MX2013014898A patent/MX337440B/es active IP Right Grant
- 2012-06-15 TW TW101121449A patent/TWI538912B/zh active
- 2012-06-15 PT PT128145919T patent/PT2721016E/pt unknown
- 2012-06-15 WO PCT/US2012/042622 patent/WO2013012500A1/en active Application Filing
- 2012-06-15 MY MYPI2013702447A patent/MY173521A/en unknown
- 2012-06-15 DK DK12814591.9T patent/DK2721016T3/en active
- 2012-06-15 SG SG2013086483A patent/SG195106A1/en unknown
- 2012-06-15 EP EP16162808.6A patent/EP3121177B1/en active Active
- 2012-06-15 ME MEP-2016-120A patent/ME02416B/me unknown
- 2012-06-15 CN CN201280039690.0A patent/CN103732583B/zh active Active
- 2012-06-15 ES ES16162808T patent/ES2688733T3/es active Active
- 2012-06-15 EA EA201490037A patent/EA023616B1/ru not_active IP Right Cessation
- 2012-06-15 CA CA2839743A patent/CA2839743C/en active Active
- 2012-06-15 EP EP12814591.9A patent/EP2721016B1/en active Active
- 2012-06-15 JP JP2014516020A patent/JP5969017B2/ja active Active
- 2012-06-15 UY UY0001034138A patent/UY34138A/es not_active Application Discontinuation
- 2012-06-15 KR KR1020147000958A patent/KR101870003B1/ko not_active Application Discontinuation
- 2012-06-15 AU AU2012284540A patent/AU2012284540B2/en active Active
- 2012-06-15 HU HUE12814591A patent/HUE029594T2/en unknown
- 2012-06-15 ES ES12814591T patent/ES2569193T3/es active Active
-
2013
- 2013-11-22 ZA ZA2013/08816A patent/ZA201308816B/en unknown
- 2013-12-09 IL IL229872A patent/IL229872A/en active IP Right Grant
- 2013-12-11 CO CO13290152A patent/CO6821953A2/es active IP Right Grant
- 2013-12-13 MA MA36564A patent/MA35184B1/fr unknown
- 2013-12-16 CL CL2013003602A patent/CL2013003602A1/es unknown
- 2013-12-17 CR CR20130671A patent/CR20130671A/es unknown
- 2013-12-17 DO DO2013000307A patent/DOP2013000307A/es unknown
-
2014
- 2014-08-20 HK HK14108527.9A patent/HK1195068A1/zh unknown
-
2016
- 2016-05-19 HR HRP20160539TT patent/HRP20160539T1/hr unknown
- 2016-05-31 SM SM201600150T patent/SMT201600150B/it unknown
- 2016-06-21 CY CY20161100556T patent/CY1117792T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2569193T3 (es) | Antagonistas de TRPV4 | |
AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
AR094314A1 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
PE20160540A1 (es) | Inhibidores de bromodominios | |
AR083026A1 (es) | Derivados de ciclohexenona y composiciones para el tratamiento del cancer de pulmon | |
EA200800476A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
AR090539A1 (es) | COMPUESTOS INHIBIDORES DE b LACTAMASA | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
AR076579A1 (es) | Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc). | |
AR089814A1 (es) | Compuestos que modulan la actividad de los proteasomas | |
AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
ES2529691T3 (es) | Derivados de 3-amino-imidazo [1,2-A] piridina como inhibidores de SGLT | |
AR085153A1 (es) | Composiciones pesticidas y procesos relacionados | |
ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
ES2571409T3 (es) | Antagonistas espiro-cíclicos de TRPV4 | |
AR089815A1 (es) | Compuestos que mejoran la actividad de los proteasomas | |
AR090103A1 (es) | Derivados ciclicos de diaminopirimidina | |
AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |